Ascendis Pharma A/S

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ASND and other ETFs, options, and stocks.

About ASND

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. 

CEO
Jan Møller Mikkelsen
CEOJan Møller Mikkelsen
Employees
Employees
Headquarters
Hellerup, Capital Region
HeadquartersHellerup, Capital Region
Founded
2006
Founded2006
Employees
Employees

ASND Key Statistics

Market cap
16.35B
Market cap16.35B
Price-Earnings ratio
25.90
Price-Earnings ratio25.90
Dividend yield
Dividend yield
Average volume
547.32K
Average volume547.32K
High today
$257.57
High today$257.57
Low today
$250.50
Low today$250.50
Open price
$251.76
Open price$251.76
Volume
324.18K
Volume324.18K
52 Week high
$282.15
52 Week high$282.15
52 Week low
$175.19
52 Week low$175.19

Stock Snapshot

Ascendis Pharma A/S(ASND) stock is priced at $255.41, giving the company a market capitalization of 16.35B. It carries a P/E multiple of 25.90.

During the trading session on 2026-08-07, Ascendis Pharma A/S(ASND) shares reached a daily high of $257.57 and a low of $250.50. At a current price of $255.41, the stock is +2.0% higher than the low and still -0.8% under the high.

Trading activity shows a volume of 324.18K, compared to an average daily volume of 547.32K.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $175.19.

Over the past 52 weeks, Ascendis Pharma A/S(ASND) stock has traded between a high of $282.15 and a low of $175.19.

ASND News

TipRanks 1d
Ascendis Pharma Posts Strong Achondroplasia Data and Early U.S. YUVIWEL Uptake

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Investing.com 1d
Ascendis reports trial data for achondroplasia treatments - Investing.com

...

Ascendis reports trial data for achondroplasia treatments - Investing.com
Simply Wall St 1d
Ascendis Pharma Could Be 20% Undervalued Following Its Recent Pullback

Ascendis Pharma (NasdaqGS:ASND) has drawn investor attention after recent trading showed the stock down about 9% over the past month, with a smaller decline ove...

Ascendis Pharma Could Be 20% Undervalued Following Its Recent Pullback

Analyst ratings

100%

of 20 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own ASND. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.